Using a fat emulsion to identify bile ducts during liver surgery to prevent bile leakage
Official title: Diagnostic Role of the "White Test" With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection- A Randomized Controlled Multicentric Superiority Trial- The BiLe-Trial (Bile Leakage Trial)
Run by Kantonsspital Aarau · NCT04523701 · Data updated 2026-11-12
This study is testing whether a special fat solution can help doctors see bile ducts better during liver surgery to prevent leaks and improve recovery for patients.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | Kantonsspital Aarau Academic / other |
| Locations | 5 sites (Aarau and 4 other locations) |
| Status | Recruiting |
| Started | March 25, 2021 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | March 14, 2025 |
| Trial ID | NCT04523701 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients scheduled for anatomical resection of two or more liver segments with simultaneous cholecystectomy.
✕Probably not a fit
Patients who have had a previous cholecystectomy where the cystic stump cannot be identified intraoperatively may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of SMOFlipid 20%, a fat emulsion, administered retrograde through the cystic duct during liver resection surgeries. The goal is to enhance the intraoperative identification of open bile ducts, which can then be sutured to prevent bile leakage, a common complication following liver surgery. By reducing the incidence of bile leakage, the study aims to decrease the need for additional interventions and improve patient outcomes within 30 days post-surgery. The trial will include patients undergoing anatomical liver resections with simultaneous cholecystectomy.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the rate of bile leakage after liver resection, leading to better recovery and fewer complications for patients.
How similar studies have gone: While the use of fat emulsions in surgical settings is not widely tested, the innovative approach of using SMOFlipid for bile duct identification represents a novel strategy that could lead to significant advancements in surgical outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who will receive an anatomical resection of two or more liver segments for any reason with simultaneous cholecystectomy in elective Setting * Patients who will receive an anatomical resection of two or more liver segments for any reason which already had a cholecystectomy if intraoperatively the cystic stump can be identified and opened * Ability of subject to understand character and individual consequences of the clinical Trial * Informed consent documented by signature Exclusion Criteria: * Previous cholecystectomy if intraoperative it is not possible to identify the cystic stump * Intraoperative hepatico-jejunostomy * Hypersensitivity to fish-, egg-, soybean or peanut protein or to any of the active ingredients or excipients * Immunosuppression, pregnancy * Emergency liver resection because of traumatic liver rupture * Enrolment of the investigator, his/her family members, employees and other dependent persons
Where it's running
-
Department of Visceral Surgery, Cantonal Hospital of Aarau
Aarau, Switzerland Recruiting -
Clarunis Basel, Universitäres Bauchzentrum Basel
Basel, Switzerland Recruiting -
Kantonsspital Luzern
Lucerne, Switzerland Recruiting -
Ospedale Regionale di Lugano
Lugano, Switzerland Recruiting -
Kantonsspital St. Gallen
Sankt Gallen, Switzerland Recruiting
Study contacts
- Principal investigator: Giulia Manzini, Dr. med. — Cantonal Hospital of Aarau, Switzerland
- Study coordinator: Giulia Manzini, Dr. med.
- Email: giulia.manzini@ksa.ch
- Phone: +41-62-8389734
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pancreatic enzyme plus oral supplements for older adults at risk of malnutrition
This will see if taking pancrelipase with oral nutritional supplements helps hospitalized adults aged 70 and older who are at risk of malnutrition absorb nutrients better.
-
Evaluating Proclarix® for better prostate cancer risk assessment
This study is testing if the Proclarix test can help better identify men at risk for significant prostate cancer when used with regular PSA tests, aiming to reduce unnecessary biopsies.
-
Evaluating taste and saliva changes in head and neck cancer patients undergoing radiation therapy
This study is testing how radiation therapy affects taste and saliva in head and neck cancer patients to see how it impacts their quality of life.
-
Comparing preoperative and postoperative radiation for brain metastases
This study tests if giving radiation before surgery for brain metastases can lower the chance of cancer spreading in the brain compared to giving it after surgery.
-
Continued nutritional support after hospital discharge for malnourished patients
This study is testing if extra nutritional support after leaving the hospital can help malnourished patients recover better and live longer compared to standard home nutrition.
-
Assessing late effects in childhood cancer survivors in Aarau, Switzerland
This study looks at the long-term health effects that childhood cancer survivors experience after their treatment to help improve their follow-up care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.